Another study explored how reducing PKM2 levels affects ovarian cancer cells sensitivity to PARPi that have shown therapeutic success in advanced ovarian carcinomavia inhibiting homologous recombination (HR) pathway (Gomez et al., 2020). The gene discussed is PKM; the disease is ovarian cancer.